Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profile 

Orcid

Education 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experience 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honors 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focus 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

Tadesse Tarik Tamir | Pharmaceutical Analysis | Best Researcher Award

Published on by Top Pharmaceutical

Tadesse Tarik Tamir | Pharmaceutical Analysis | Best Researcher Award

Mr. Tadesse Tarik Tamir, College of Medicine and Health Sciences, University of Gondar, Ethiopia

Tadesse Tarik Tamir is a dedicated lecturer and researcher at the University of Gondar, Ethiopia 🎓. With a Master’s in Pediatrics and Child Health Nursing and an MPH in Epidemiology, he actively contributes to teaching, research, and community service. His expertise spans public health, epidemiology, and child healthcare 🏥. Tadesse has published several Q1-ranked research articles on childhood nutrition, vaccination, and PTSD in children 📑. Proficient in SPSS, STATA, R, and GIS 📊, he is committed to advancing healthcare research and education. His work continues to impact public health policies and child welfare across low- and middle-income countries 🌍.

Publication Profile

orcid

Education

Tadesse Tarik Tamir 🎓 is a dedicated healthcare professional from Gondar, Ethiopia 🇪🇹. He is currently pursuing an MPH in Epidemiology 🦠 at the University of Gondar (since November 2022). Previously, he earned an MSc in Pediatrics and Child Health Nursing 👶🩺 (2019–2021) and a BSc in Nursing 🏥 (2014–2018) from the same university. His commitment to academia also led him to obtain a Diploma in Higher Education 📚 (2021–2022). With a strong educational background and expertise in nursing and epidemiology, Tadesse is devoted to improving public health and child healthcare in Ethiopia. 🌍✨

Experience 

Tadesse Tarik Tamir 🎓 is a dedicated educator and researcher at the University of Gondar 🇪🇹. Since July 2021, he has been serving as a Lecturer 🏫, actively engaged in teaching, research, and community service. Prior to this, he worked as an Assistant Lecturer 📚 (2019–2021), contributing to academic excellence and knowledge dissemination. His journey in academia began as a Graduate Assistant II 🏅 (2018–2019), where he honed his teaching and research skills. With a strong passion for education and public health, Tadesse continues to inspire students and contribute to impactful research in Ethiopia. 🌍✨

Networks and Membership

Tadesse Tarik Tamir 🎓 is an active contributor to academia and professional networks. Since 2016, he has served as an Editorial Board Member for BMC Public Health 📝, playing a vital role in scientific publishing. He has been a proud member of the Ethiopian Nursing Association (ENA) 🏥 since 2015, advocating for nursing excellence. His commitment to social impact extends to his role at the Menna Elderly and Mentally Challenging Support Center ❤️. Additionally, since 2021, he has been an Executive Member of the Ethiopian Teachers’ Association 📚, supporting educators and academic development in Ethiopia 🇪🇹. 🌍✨

Research Focus

Tadesse Tarik Tamir’s research focuses on public health 🏥, epidemiology 📊, and child health 👶 across low- and middle-income countries. His work extensively explores childhood vaccination 💉, nutritional health 🥦, infectious diseases 🦠, and maternal and neonatal mortality 👩‍🍼. He also investigates mental health disorders 🧠, particularly post-traumatic stress disorder (PTSD) in children. Through systematic reviews, meta-analyses, and spatial epidemiology, he provides critical insights into health disparities 🌍, aiming to influence policy decisions 📜 and improve healthcare outcomes. His high-impact Q1 journal publications 📄 reflect his leadership in global health research.

Publication Top Notes

Coverage of complete basic childhood vaccination and its variation by basic characteristics among children aged 12–23 months in 41 low- and middle-income countries: A Meta-analysis of demographic and health survey reports between 2015 and 2025

Minimum dietary diversity and its determinants among lactating mothers in five Sub-Saharan African countries: A multilevel analysis

Spatial variation and predictors of anemia among women of reproductive age in Mozambique, 2022/23: a multiscale geographically weighted regression

Prevalence of depression among primary caregivers of patients with cancer in Africa: a systematic review and meta-analysis study

Only three out of ten women received adequate postnatal care in sub-Saharan Africa: evidence from 20 countries demographic and health surveys (2015–2022)

Determinants of pressure to conceive among reproductive age women in Sub-Saharan Africa: A multilevel analysis of recent Demographic and Health Surveys in five countries

Childhood wasting and associated factors in Africa: evidence from standard demographic and health surveys from 35 countries

Prevalence and Determinants of Home Delivery among Women with Easy Access to Health Facilities in Sub‑Saharan African Countries: A Multi‑level Mixed Effect Analysis

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat